128 related articles for article (PubMed ID: 38845389)
21. Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics.
Zhang M; You X; Ke M; Jiao Z; Wu H; Huang P; Lin C
J Pharm Sci; 2019 Aug; 108(8):2781-2790. PubMed ID: 30928308
[TBL] [Abstract][Full Text] [Related]
22. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models.
Gueorguieva I; Ogungbenro K; Graham G; Glatt S; Aarons L
Comput Methods Programs Biomed; 2007 Apr; 86(1):51-61. PubMed ID: 17292995
[TBL] [Abstract][Full Text] [Related]
23. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
[TBL] [Abstract][Full Text] [Related]
24. Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations.
Jeong HC; Kim MG; Wei Z; Lee KR; Lee J; Song IS; Shin KH
Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745870
[TBL] [Abstract][Full Text] [Related]
25. Optimal sampling times for a drug and its metabolite using SIMCYP(®) simulations as prior information.
Dumont C; Mentré F; Gaynor C; Brendel K; Gesson C; Chenel M
Clin Pharmacokinet; 2013 Jan; 52(1):43-57. PubMed ID: 23212609
[TBL] [Abstract][Full Text] [Related]
26. Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling.
Wu K; Li X; Zhou Z; Zhao Y; Su M; Cheng Z; Wu X; Huang Z; Jin X; Li J; Zhang M; Liu J; Liu B
Front Pharmacol; 2024; 15():1330855. PubMed ID: 38434709
[TBL] [Abstract][Full Text] [Related]
27. Development and verification of a physiologically based pharmacokinetic model of dronedarone and its active metabolite N-desbutyldronedarone: Application to prospective simulation of complex drug-drug interaction with rivaroxaban.
Leow JWH; Ang XJ; Chan ECY
Br J Clin Pharmacol; 2023 Jun; 89(6):1873-1890. PubMed ID: 36683488
[TBL] [Abstract][Full Text] [Related]
28. A semi-physiologically-based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human.
Wang J; Xia S; Xue W; Wang D; Sai Y; Liu L; Liu X
Eur J Pharm Sci; 2013 Nov; 50(3-4):290-302. PubMed ID: 23916407
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.
Kerbusch T; Milligan PA; Karlsson MO
Br J Clin Pharmacol; 2004 Feb; 57(2):170-80. PubMed ID: 14748816
[TBL] [Abstract][Full Text] [Related]
30. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
31. Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio.
Obach RS; Lin J; Kimoto E; Duvvuri S; Nicholas T; Kadar EP; Tremaine LM; Sawant-Basak A
Drug Metab Dispos; 2018 Feb; 46(2):89-99. PubMed ID: 29150544
[TBL] [Abstract][Full Text] [Related]
32. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
Loisios-Konstantinidis I; Dressman J
Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
[TBL] [Abstract][Full Text] [Related]
33. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Mendell J; Johnson L; Chen S
J Clin Pharmacol; 2015 Dec; 55(12):1395-405. PubMed ID: 26011596
[TBL] [Abstract][Full Text] [Related]
34. A single-dose study investigating the pharmacokinetics and pharmacodynamics of edoxaban at 30-90 mg in healthy Chinese volunteers.
Chen X; Liu D; Wu Y; Song H; Liu Y; Jiang J; Hu P
Xenobiotica; 2017 Jul; 47(7):592-599. PubMed ID: 27560456
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Bathala MS; Masumoto H; Oguma T; He L; Lowrie C; Mendell J
Drug Metab Dispos; 2012 Dec; 40(12):2250-5. PubMed ID: 22936313
[TBL] [Abstract][Full Text] [Related]
36. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.
Yellepeddi V; Rower J; Liu X; Kumar S; Rashid J; Sherwin CMT
Clin Pharmacokinet; 2019 Jan; 58(1):1-13. PubMed ID: 29777528
[TBL] [Abstract][Full Text] [Related]
37. Development and application of a physiologically based pharmacokinetic model for triadimefon and its metabolite triadimenol in rats and humans.
Crowell SR; Henderson WM; Kenneke JF; Fisher JW
Toxicol Lett; 2011 Aug; 205(2):154-62. PubMed ID: 21641977
[TBL] [Abstract][Full Text] [Related]
38. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration.
Wen HN; He QF; Xiang XQ; Jiao Z; Yu JG
Thromb Res; 2022 Oct; 218():24-34. PubMed ID: 35985100
[TBL] [Abstract][Full Text] [Related]
39. Physiologically-Based Pharmacokinetic Modeling for Drug-Drug Interactions of Procainamide and
Jeong YS; Balla A; Chun KH; Chung SJ; Maeng HJ
Pharmaceutics; 2019 Mar; 11(3):. PubMed ID: 30845766
[TBL] [Abstract][Full Text] [Related]
40. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
Chen Y; Zhao K; Liu F; Li Y; Zhong Z; Hong S; Liu X; Liu L
Drug Metab Dispos; 2018 Jun; 46(6):897-907. PubMed ID: 29618575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
